|Roth Capital Partners||Michael Higgins|
|Rodman & Renshaw (A unit of H.C. Wainwright & Co.)||Raghuram Selvaraju, Ph.D.|
|IFS Securities||David Bouchey, Ph.D.|
|Maxim Group LLC||Jason McCarthy, Ph.D.|
Arch Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Arch Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Arch Therapeutics, Inc. or its management. Arch Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.